Table 2

Results of cost by indication, number of patients and budget impact

mCRCmBCmNSCLCmRCCmOCmCCTotal
Year 1No of patientsCostNo of patientsCostNo of patientsCostNo of patientsCostNo of patientsCostNo of patientsCostNo of patientsCost
Without biosimilarsOriginal4607€134 552 572314€9 046 010338€19 482 62425€1 430 3481592€55 141 009128€7 380 7887004€227 033 352
With biosimilarsOriginal3225€127 702 501220€8 585 477236€18 490 76417€1 357 5291114€52 333 78190€7 005 0324902€215 475 084
Biosimilar1382941017478382100
Incremental cost€6 850 071€339 719€991 860€72 819€2 807 229€375 756€11 558 268
Budget impact5.1%
Year 2Without biosimilarsOriginal7094€207 192 952444€12 815 181478€27 600 38438€2 178 2922396€82 971 757172€9 904 64210 622€342 663 209
With biosimilarsOriginal3547€189 581 552222€11 725 890239€25 254 35219€1 993 1371198€75 919 15886€9 062 7485311€313 536 836
Biosimilar3547222239191198865311
Incremental cost€17 611 401€1 089 290€2 346 033€185 155€7 052 599€841 895€29 126 373
Budget impact8.5%
Year3Without biosimilarsOriginal8081€236 020 306477€13 757 473513€29 629 82443€2 459 4082680€92 811 413179€10 334 65111 973€385 013 076
With biosimilarsOriginal1616€203 921 54595€11 886 457103€25 600 1689€2 124 929536€80 189 06136€8 929 1382395€332 651 297
Biosimilar64653824113421441439579
Incremental cost€32 098 762€1 871 016€4 029 656€334 480€12 622 352€1 405 513€52 361 778
Budget impact13.6%
  • mBC, metastatic breast cancer; mCC, metastatic cervical cancer; mCRC, metastatic colorectal cancer; mNSCLC, metastatic, unresecable or relapsed non-small cell lung cancer; mOC, metastatic epithelial ovarian, fallopian tube or peritoneal cancer; mRCC, metastatic renal cell carcinoma.